Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Reported by The New England Journal of Medicine. Read the original →
The headline indicates that the article discusses the effects of Lixisenatide in patients who have both Type 2 diabetes and acute coronary syndrome. It suggests a focus on the relationship between this peptide and the health outcomes of these patients. Further details are not provided in the description.
Summarised by a model from The New England Journal of Medicine's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.
On file here
Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.
- Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli-D Study.Human · RCT · n=582 · 2026
- Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli-D Study.Human · RCT · n=582 · 2026
- Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors Among Patients with Type 1 Diabetes: A Nationwide Register-Based Cohort Study.Human · Observational · n=72698 · 2026
What the headline doesn't tell you
- Lixisenatide has 23 studies on file, 12 of them in humans, the newest published 2026.
Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.